Denopamine
Denopamine is a selective beta-1 adrenergic agonist used, mainly in Japan, as an oral inotropic agent for chronic heart failure. Unlike the beta-2 cutting agents in this family, its selectivity is for the beta-1 cardiac receptor, so it increases cardiac contractility rather than promoting fat loss. It is included as a contrasting, cardiac-selective member of the beta-agonist class.
01 Overview
Denopamine is an orally active, selective beta-1 adrenergic receptor agonist developed and used in Japan for the treatment of chronic congestive heart failure. By stimulating cardiac beta-1 receptors it increases myocardial contractility (positive inotropy) with relatively little effect on heart rate or peripheral vessels compared with non-selective agents, allowing oral outpatient use where intravenous inotropes would otherwise be needed.
It differs fundamentally from the beta-2 agonists used for cutting: its selectivity is cardiac, so it has no thermogenic or fat-loss rationale and would instead impose direct cardiac workload. As with all inotropic support in heart failure, chronic beta-1 stimulation carries theoretical risks of arrhythmia and, as seen historically with the drug class, potential adverse effects on long-term outcomes. Its evidence base is moderate and largely regional.
02 Mechanism
Selective beta-1 adrenergic agonist. Stimulates cardiac beta-1 receptors to raise cyclic AMP in myocytes, increasing contractility (positive inotropy) with comparatively little chronotropic or beta-2 effect.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Heart failure | 5–30 mg/day | Oral | Typically ~5-10 mg three times daily for chronic heart failure (regional labelling). |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Increased cardiac contractilityRaises myocardial contractility, improving output in chronic heart failure via oral dosing. | positive inotropy | Clinical | |
| Symptom improvement in heart failureImproves heart-failure symptoms and exercise tolerance in the populations studied. | symptomatic | Observational |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| ArrhythmiaBeta-1 stimulation can provoke arrhythmias, a class risk of positive inotropes in heart failure. | Severe | Uncommon | Clinical | |
| PalpitationsPalpitations from cardiac beta-1 stimulation. | Mild | Common | Clinical | |
| Increased myocardial oxygen demandPositive inotropy raises cardiac oxygen consumption, a concern in coexisting ischaemic heart disease. | Moderate | In ischaemic disease | Clinical |